Homocysteine levels and treatment effect in the PROspective Study of Pravastatin in the Elderly at Risk.
Bottom Line: Fatal and nonfatal CHD and mortality.In the placebo group, participants with a high homocysteine level (n = 588) had a 1.8 higher risk (95% confidence interval (CI) = 1.2-2.5, P = .001) of fatal and nonfatal CHD than those with a low homocysteine level (n = 597).With pravastatin treatment, this group has the highest absolute risk reduction and the lowest NNT to prevent fatal and nonfatal CHD.
Affiliation: Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands.Show MeSH
Related in: MedlinePlus
Mentions: Figure 1 shows the cumulative incidence of fatal and nonfatal CHD and all-cause mortality for the three homocysteine groups in the placebo group. Participants with medium homocysteine levels had no greater risk of fatal and nonfatal CHD than those with low homocysteine (HR = 1.1, 95% CI = 0.76–1.6, P = .57), but those with high homocysteine had a 1.8 times greater risk (95% CI = 1.2–2.5, P = .001). For overall mortality, the HRs were 1.0 (95% CI = 0.67–1.5, P = .99) and 1.7 (95% CI = 1.2–2.5, P = .003), respectively. These estimates did not change after additional adjustments for history of CVD; Framingham risk factors; or CRP, HDL-C, and creatinine clearance (data not shown).
Affiliation: Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands.